<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01115582</url>
  </required_header>
  <id_info>
    <org_study_id>CAC-001-01</org_study_id>
    <nct_id>NCT01115582</nct_id>
  </id_info>
  <brief_title>Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis</brief_title>
  <official_title>Open Label, Single Center, Nonrandomized Study Comparing Efficacy of To Be Marketed Cholic Acid With That of the Currently Used Formulation of Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retrophin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retrophin, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in a small population of children who have inborn errors of bile acid
      synthesis who are currently taking established doses of the currently used cholic acid
      capsules prepared at the Cincinnati Children's Hospital Pharmacy. The study is designed to
      compare the efficacy of these currently used capsules with the efficacy of the same treatment
      provided in a cholic acid capsule that is made by a company that will be marketed after FDA
      approval.

      At baseline, patients receive established doses of cholic acid capsules prepared at the
      Cincinnati Children's Hospital Medical Center Pharmacy. During the study, patients receive
      the same treatment provided in the to-be-marketed (TBM) cholic acid capsule. Hence, patients
      serve as their own controls, with baseline values presenting the reference value (CCHMC
      cholic acid capsule) and values after 30 days treatment presenting the value for the
      investigational treatment (TBM cholic acid capsule).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bile acids are end products of cholesterol metabolism. Individuals with inborn errors of bile
      acid synthesis lack the enzymes needed to synthesize the primary bile acids cholic acid and
      chenodeoxycholic acid (CDCA). These conditions are serious and account for approximately 1%
      of cases presenting as idiopathic cholestatic liver disease. The liver disease associated
      with these inborn errors in bile acid synthesis is progressive and, if untreated, may lead to
      death from cirrhosis and liver failure.

      Monotherapy with cholic acid is considered the most appropriate therapeutic strategy to treat
      inborn errors in bile acid synthesis because it provides a stimulus for bile flow and
      inhibits endogenous production and accumulation of potentially hepatotoxic and cholestatic
      bile acid precursors, while additionally facilitating the absorption of fats and fat-soluble
      vitamins. At therapeutic doses, adverse effects are not generally observed and as such,
      cholic acid has become the treatment of choice at the Cincinnati Children's Hospital since
      1994.

      This study will bridge data on the effectiveness of a standardized manufactured preparation
      to data obtained from patients originally treated with the currently used cholic acid
      capsules formulated in the CCHMC Pharmacy before being switched to the manufactured
      preparation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Transaminases</measure>
    <time_frame>At baseline and after 30 days of treatment</time_frame>
    <description>Concentration of serum alanine transaminase (ALT) and aspartate transaminase (AST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum and Urine Bile Acids</measure>
    <time_frame>At baseline (BL) and after 30 days of treatment (D30)</time_frame>
    <description>Concentration of bile acids in serum (S) and urine (U). (abbreviations: chol.=cholenoic; monohydro=monohydroxy; dihydro=monohydro)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Total of 30 days, i.e. from the time point the patients entered into the study up to the end of treatment</time_frame>
    <description>Total number of patients with any adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>At baseline and after 30 days of treatment</time_frame>
    <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>At baseline (BL) and after 30 days of treatment (D30)</time_frame>
    <description>Total number of patients with abnormal findings from general physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin</measure>
    <time_frame>At baseline and after 30 days of treatment</time_frame>
    <description>Concentration of total bilirubin in serum</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Inborn Errors of Bile Acid Synthesis</condition>
  <arm_group>
    <arm_group_label>Cholic Acid Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manufactured cholic acid capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholic acid</intervention_name>
    <description>The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.
Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child.</description>
    <arm_group_label>Cholic Acid Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have stable transaminase levels within 2 times the upper limits of the normal
             range.

          -  must have a diagnosis of an inborn error of bile acid synthesis.

          -  must have signed the written informed consent/assent document before study start.

          -  must be currently receiving currently used cholic acid therapy under IND 45,470.

          -  must be willing and able to comply with all study assessments and procedures.

          -  must be able to make two visits (Visit 1 and Visit 2) to the study site.

        Exclusion Criteria:

          -  is not currently receiving cholic acid therapy for inborn errors of bile acid
             synthesis under IND 45,470.

          -  is unable or unwilling to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James E Heubi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bove KE, Heubi JE, Balistreri WF, Setchell KD. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol. 2004 Jul-Aug;7(4):315-34. Epub 2004 Jul 15. Review.</citation>
    <PMID>15383928</PMID>
  </reference>
  <reference>
    <citation>Gonzales E, Gerhardt MF, Fabre M, Setchell KD, Davit-Spraul A, Vincent I, Heubi JE, Bernard O, Jacquemin E. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology. 2009 Oct;137(4):1310-1320.e1-3. doi: 10.1053/j.gastro.2009.07.043. Epub 2009 Jul 19.</citation>
    <PMID>19622360</PMID>
  </reference>
  <reference>
    <citation>Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin Liver Dis. 2007 Aug;27(3):282-94. Review.</citation>
    <PMID>17682975</PMID>
  </reference>
  <reference>
    <citation>Jacquemin E., Gerhardt M, Cresteil D, Fabre M, Taburet AM, Hadchouel M, Trivin F, Stechell KDR and Bernard O. Long-term effects of bile acid therapy in children with defects of primary bile acid synthesis: 3ß-Hydroxy-C27-steroid dehydrogenase/isomerase and Delta4-3-Oxosteroid 5ß-reductase deficiencies. In: van Berge Henegouwen GP, et al. (eds): Falk Symposium No 120: Biology of Bile Acids in Health and Disease. Kluwer Academic Publishers, Dordrecht/Boston/London; 2001:278-282.</citation>
  </reference>
  <reference>
    <citation>Setchell KD, Heubi JE. Defects in bile acid biosynthesis--diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S17-22. Review.</citation>
    <PMID>16819396</PMID>
  </reference>
  <reference>
    <citation>Setchell KDR, et al. A unique case of cerebrotendinous xantomatosis presenting in infancy with cholestatic liver disease further highlights bile acid synthetic defects as an important category of metabolic liver disease. In: van Berge Henegouwen GP et al. (ed): Falk Symposium No. 120: Biology of Bile Acids in Health and Disease. Boston: Kluwer Academic Publishers; 2001.</citation>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <results_first_submitted>July 20, 2016</results_first_submitted>
  <results_first_submitted_qc>October 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <disposition_first_submitted>May 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2013</disposition_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inborn Errors</keyword>
  <keyword>Bile Acid</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Liver Disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Cholic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this single-arm study, patients served as their own controls: Reference was presented by the baseline value, when patients received cholic acid capsules prepared by the Cincinnati Children's Hospital Medical Center; Investigational Treatment was the to-be-marketed (TBM) cholic acid capsule administered to patients for 30 days treatment duration.</recruitment_details>
      <pre_assignment_details>The study was performed in patients with inborn defects of bile acid synthesis currently receiving cholic acid capsules prepared by the Cincinnati Children’s Hospital Medical Center (CCHMC) under IND 45,470. The study planned to include 25 patients; but only 16 patients fulfilled eligibility criteria and were willing to travel to the CCHMC.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholic Acid</title>
          <description>All patients entered and treated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cholic Acid</title>
          <description>All patients entered and treated</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Transaminases</title>
        <description>Concentration of serum alanine transaminase (ALT) and aspartate transaminase (AST)</description>
        <time_frame>At baseline and after 30 days of treatment</time_frame>
        <population>All patients entered and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>All patients entered and treated</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Transaminases</title>
          <description>Concentration of serum alanine transaminase (ALT) and aspartate transaminase (AST)</description>
          <population>All patients entered and treated</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum and Urine Bile Acids</title>
        <description>Concentration of bile acids in serum (S) and urine (U). (abbreviations: chol.=cholenoic; monohydro=monohydroxy; dihydro=monohydro)</description>
        <time_frame>At baseline (BL) and after 30 days of treatment (D30)</time_frame>
        <population>All patients entered and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>All patients entered and treated</description>
          </group>
        </group_list>
        <measure>
          <title>Serum and Urine Bile Acids</title>
          <description>Concentration of bile acids in serum (S) and urine (U). (abbreviations: chol.=cholenoic; monohydro=monohydroxy; dihydro=monohydro)</description>
          <population>All patients entered and treated</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>U, BL: 3β,7α-dihydroxy-Δ5 sulfate m/z 469</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.37" spread="35.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, D30: 3β,7α-dihydroxy-Δ5 sulfate m/z 469</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.762" spread="3.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, BL: 3β,7α,12α-trihydroxy-Δ5 sulfate m/z 485</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.11" spread="42.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, D30: 3β,7α,12α-trihydroxy-Δ5 sulfate m/z 485</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.011" spread="2.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, BL: 3β,7α-dihydroxy-Δ5 gluycosulfate m/z 526</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.85" spread="474.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, D30: 3β,7α-dihydroxy-Δ5 gluycosulfate m/z 526</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.958" spread="29.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U,BL: 3β,7α,12α-trihydroxy-Δ5 glycosulfate m/z 542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.43" spread="337.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U,D30: 3β,7α,12α-trihydroxy-Δ5 glycosulfate m/z542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.421" spread="7.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,BL: Glyco-3-oxo-7-α,12α-dihydroxy-4-chol. m/z460</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,D30: Glyco-3-oxo-7-α,12α-dihydroxy-4-chol.m/z460</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,BL:Glyco-3-oxo-7-α,12α-monohydroxy-4-chol.m/z444</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,D30:Glyco-3-oxo-7-α,12α-monohydro.-4-chol.m/z444</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S, BL: Tauro-3-oxo-7-α,12α-dihydroxy-4-chol.m/z510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,D30: Tauro-3-oxo-7-α,12α-dihydroxy-4-chol.m/z510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.490" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,BL:Tauro-3-oxo-7-α,12α-monohydroxy-4-chol.m/z498</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S,D30:Tauro-3-oxo-7-α,12α-monohydro.-4-chol.m/z498</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, BL: Total 3β-hydroxy-Δ5 bile acids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.77" spread="889.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U, D30: Total 3β-hydroxy-Δ5 bile acids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.148" spread="43.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S, BL: Total 3-oxo-Δ4 bile acids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S, D30: Total 3-oxo-Δ4 bile acids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.705" spread="0.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Total number of patients with any adverse events</description>
        <time_frame>Total of 30 days, i.e. from the time point the patients entered into the study up to the end of treatment</time_frame>
        <population>All patients entered and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>All patients entered and treated</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Total number of patients with any adverse events</description>
          <population>All patients entered and treated</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP)</description>
        <time_frame>At baseline and after 30 days of treatment</time_frame>
        <population>All patients entered and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>All patients entered and treated</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP)</description>
          <population>All patients entered and treated</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Examination</title>
        <description>Total number of patients with abnormal findings from general physical examination</description>
        <time_frame>At baseline (BL) and after 30 days of treatment (D30)</time_frame>
        <population>All patients entered and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>All patients entered and treated</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Examination</title>
          <description>Total number of patients with abnormal findings from general physical examination</description>
          <population>All patients entered and treated</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL, N patients with abnormal physical findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D30, N patients with abnormal physical findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin</title>
        <description>Concentration of total bilirubin in serum</description>
        <time_frame>At baseline and after 30 days of treatment</time_frame>
        <population>All patients entered and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Cholic Acid</title>
            <description>All patients entered and treated</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin</title>
          <description>Concentration of total bilirubin in serum</description>
          <population>All patients entered and treated</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D30, total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Total of 30 days, i.e. from the time point the patients entered into the study up to the end of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cholic Acid</title>
          <description>All patients entered and treated</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased/low 250H/Vit D</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Decreased Vitamin A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Nosebleed</sub_title>
                <description>In the clinical study Report, the Event was counted towards the Body System &quot;Eye, ear, nose, throat&quot;</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Retrophin Medical Information</name_or_title>
      <organization>Retrophin, Inc.</organization>
      <phone>1-877-659 ext 5518</phone>
      <email>medinfo@retrophin.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

